by CytoPrevent | Sep 26, 2022 | What’s new on CytoPrevent
Seth Eisenberg (Professional Practice Coordinator, Infusion Services, Seattle Cancer Care Alliance) Hazardous Drugs Risks associated with exposure to hazardous drugs (HDs) such as chemotherapy, have been well documented over the past two decades and...
by CytoPrevent | Aug 31, 2022 | What’s new on CytoPrevent
ISOPP Standards for the Safe Handling of Cytotoxics Since the initial release of the International Society of Oncology Pharmacy Practitioners (ISOPP) Standards for the Safe Handling of Cytotoxic Drugs in 2007, much has evolved in oncology pharmacy. Safe...
by CytoPrevent | Jan 11, 2022 | What’s new on CytoPrevent
Press Release of the European Parliament On 9 December 2021, Parliament’s Special Committee on Beating Cancer adopted its final proposals on how to strengthen the EU’s role in the fight against cancer. They include the following: 1. Taking stronger EU...
by CytoPrevent | Dec 30, 2021 | What’s new on CytoPrevent
Press Release – 16 December 2021 The Stop Cancer at Work Campaign today welcomes the provisional political agreement by the European Parliament and European Council to include for the first time greater protection and reference to reprotoxic substances...
by CytoPrevent | Dec 26, 2021 | What’s new on CytoPrevent
Background The toxic effects of antineoplastic drugs used for cancer treatment have been well known since their introduction in the 1940s. However, beyond the patient safety concerns arising from the necessary therapeutic use of these drugs, the occupational risks to...
by CytoPrevent | Dec 22, 2021 | What’s new on CytoPrevent
Official Press Release from the Council Presidency and the European Parliament The Council presidency and the European Parliament have reached a provisional deal to update the carcinogens and mutagens directive, an EU law to protect workers from risks related...